Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 5

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
— — $— $— $— $(1,867)$(1,867)$(28)$(1,895)Balance at June 30, 202563,474,253 $6 729,320 $— $683,962 $(330,757)$520 $353,731 $4,213 $357,944 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— $— — $— $3,698 $— $— $3,698 $10 $3,708 Net loss for the three months ended September 30, 2025— $— — $— $— $(69,729)$— $(69,729)$(965)$(70,694)Other comprehensive loss— $— — $— $— $— $(244)$(244)$(3)$(247)Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares203,142 $— (203,142)$— $968 $— $2 $970 $(970)$— Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan27,149 $— — $— $480 $— $— $480 $— $480 Balance at September 30, 202563,704,544 $6 526,178 $— $689,108 $(400,486)$278 $288,906 $2,285 $291,191 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

5

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Nine Months Ended September 30, (in thousands)    20252024Cash flow from operating activitiesNet loss$(167,303)$(74,849)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization1,8651,021Share-based compensation expense9,3085,348Net periodic pension benefit gain for the qualified pension plan(27)(3)Other non-cash items(928)251Changes in operating assets and liabilities:Other